title: Health-care costs of losartan and candesartan in the primary treatment of hypertension.
abstract: A recent study of two widely used angiotensin receptor blockers reported a reduced risk of cardiovascular events (-14.4%) when using candesartan compared with losartan in the primary treatment of hypertension. In addition to clinical benefits, costs associated with treatment strategies must be considered when allocating scarce health-care resources. The aim of this study was to assess resource use and costs of losartan and candesartan in hypertensive patients. Resource use (drugs, outpatient contacts, hospitalizations and laboratory tests) associated with losartan and candesartan treatment was estimated in 14,100 patients in a real-life clinical setting. We electronically extracted patient data from primary care records and mandatory Swedish national registers for death and hospitalization. Patients treated with losartan had more outpatient contacts (+15.6%), laboratory tests (+13.8%) and hospitalizations (+13.8%) compared with the candesartan group. During a maximum observation time of 9 years, the mean total costs per patient were 10,369 Swedish kronor (95% confidence interval: 3109-17,629) higher in the losartan group. In conclusion, prescribing candesartan for the primary treatment of hypertension results in lower long-term health-care costs compared with losartan.
authors.affiliation: Health Economics Department, AstraZeneca, Södertälje, Sweden. martin.x.henriksson@astrazeneca.com
authors.forename: M
authors.initials: M
authors.lastname: Henriksson
authors.forename: D
authors.initials: D
authors.lastname: Russell
authors.forename: J
authors.initials: J
authors.lastname: Bodegard
authors.forename: S
authors.initials: S
authors.lastname: Kjeldsen
authors.forename: P
authors.initials: P
authors.lastname: Hasvold
authors.forename: J
authors.initials: J
authors.lastname: Stålhammar
authors.forename: L-Å
authors.initials: LÅ
authors.lastname: Levin
mesh_terms: D054058:Acute Coronary Syndrome / Q000209:etiology / Q000517:prevention & control; D047228:Angiotensin II Type 1 Receptor Blockers / Q000191:economics / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000191:economics / Q000627:therapeutic use; D001562:Benzimidazoles / Q000191:economics / Q000627:therapeutic use; D001713:Biphenyl Compounds; D002545:Brain Ischemia / Q000209:etiology / Q000517:prevention & control; D016527:Drug Costs; D017048:Health Care Costs; D006760:Hospitalization / Q000191:economics; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000191:economics / Q000503:physiopathology / Q000628:therapy*; D008134:Long-Term Care / Q000191:economics; D019808:Losartan / Q000191:economics / Q000627:therapeutic use; D012042:Registries; D013548:Sweden; D013777:Tetrazoles / Q000191:economics / Q000627:therapeutic use
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; D019808:Losartan; C081643:candesartan